title: Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers.
abstract: OBJECTIVE
  We studied the growth and development of children prenatally exposed to telbivudine used to treat chronic hepatitis B virus (HBV) infection in their mothers.
  
  
  METHODS
  Maternal abnormalities during pregnancy and delivery and infant congenital anomalies, physical development status, developmental quotient (DQ), HBV vertical transmission status, and HBV vaccination outcomes of 54 infants were evaluated (2010-2013).
  
  
  RESULTS
  No fetal abnormalities were observed during pregnancy or delivery. Postpartum, three infants (5.56%) had abnormalities: ankyloglossia, cutaneous hemangioma, and vaginal canal leak. Height and weight were within the normal range at birth and at 6 weeks, but were higher than the reference at 12 months (p<0.05). Body mass index increased gradually with age (p<0.05). DQ scores were normal (84.81%, 229/270) in 37 children (68.52%), abnormal or suspicious for a developmental delay (15.19%, 41/270) in 17 children (31.48%), and indicated a developmental delay (4.07%, 11/270) in seven children (12.96%). There were no significant differences in developmental delay between children prenatally exposed to telbivudine and controls (p>0.05). HBV vertical transmission was successfully blocked in all infants. The effective HBV vaccination rate was 98.15% (53/54).
  
  
  CONCLUSIONS
  The growth and development of children prenatally exposed to telbivudine was normal, indicating that telbivudine treatment during pregnancy is safe and effective.
authors.affiliation: Department of Pediatrics, Beijing Ditan Hospital affiliated with Capital Medical University, Beijing, China.
authors.forename: Huihui
authors.initials: H
authors.lastname: Zeng
authors.affiliation: Department of Hepatology, Beijing Ditan Hospital affiliated with Capital Medical University, Beijing, China.
authors.forename: Haodong
authors.initials: H
authors.lastname: Cai
authors.affiliation: Department of Children's Healthcare, Beijing Children's Hospital affiliated with Capital Medical University, Beijing, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Pediatrics, Beijing Children's Hospital affiliated with Capital Medical University, Beijing 100045, China. Electronic address: Ying_116sh@sohu.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Shen
mesh_terms: D000328:Adult; D000072676:Ankyloglossia; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015992:Body Mass Index; D001835:Body Weight; D002657:Child Development; D002681:China / Q000453:epidemiology; D036861:Delivery, Obstetric; D005260:Female; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D008431:Maternal-Fetal Exchange; D009056:Mouth Abnormalities / Q000453:epidemiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011297:Prenatal Exposure Delayed Effects / Q000453:epidemiology*; D012016:Reference Values; D000077712:Telbivudine; D013936:Thymidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D000077712:Telbivudine; D013936:Thymidine
keywords: Children; Chronic hepatitis B; Development; Growth; Mothers; Telbivudine